
French pharmaceutical giant Sanofi-Aventis has launched an $18.5 billion bid for US biotech company Genzyme Corp.
The bid is said to be aimed at capturing Genzyme’s drugs for high cholesterol and its lucrative treatments for rare genetic disorders.
Sanofi's now hostile $69-per-share offer values the Cambridge, Massachusetts-based company at $18.5 billion—the same as its friendly offer made privately to Genzyme’s management in July. Genzyme rebuffed that approach.